Effect of fluocinolone acetonide (0.1%) treatment in oral lichen planus patients on salivary lactoferrin levels and Candida colonization: a prospective study

• Published in: BMC oral health Vol. 22; no. 1; p. 58
• Main Authors: Saengprasittichok, Nuttapong, Sucharitakul, Jeerus, Matangkasombut, Oranart, Prapinjumrune, Chanwit
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04-03-2022; BioMed Central; BMC
• Subjects: Candida; Care and treatment; Control; Diagnosis; Dosage and administration; Enzyme-linked immunosorbent assay; Fluocinolone; Fluocinolone acetonide; Fluocinolone Acetonide - therapeutic use; Health aspects; Humans; Identification and classification; Lactoferrin; Lactoferrin - metabolism; Lactoferrin - therapeutic use; Lactoferrins; Lichen planus; Lichen Planus, Oral - drug therapy; Lichen Planus, Oral - metabolism; Measurement; Methods; Oral lichen planus; Prospective Studies; Risk factors; Topical medication; Topical steroid; Thailand; Oral lichen planus; Lactoferrin; Topical steroid; Candida
• ISSN: 1472-6831; 1472-6831
• DOI: 10.1186/s12903-022-02096-3

Although topical steroids are an effective treatment for oral lichen planus, they can have suppressive effects on oral immunity and predispose the patients to Candida overgrowth. Lactoferrin is a crucial local immunity protein in the oral cavity with important antimicrobial activity. The aim of this study was to prospectively investigate salivary lactoferrin secretion levels and Candida colonization in oral lichen planus patients treated with fluocinolone acetonide 0.1% in orabase.
Saliva samples were collected from 15 oral lichen planus subjects who had never received topical steroid treatment prior to this study and 15 healthy volunteers to determine their salivary lactoferrin levels using an enzyme-linked immunosorbent assay and to investigate the presence of oral Candida species at baseline and 3 months after treatment with fluocinolone acetonide 0.1% in orabase. Statistical analysis was performed to compare lactoferrin secretion and Candida colonization levels between the groups using the Mann-Whitney U test for independent data or the Wilcoxon Signed-Rank test for paired data.
The salivary lactoferrin secretion level was not significantly different between the control group and oral lichen planus patients or between before and after treatment with fluocinolone acetonide 0.1% in orabase (P > 0.05). Candida was detected in 11 (73.33%) healthy volunteers, 8 (53.33%) oral lichen planus patients before treatment, and 9 (60%) oral lichen planus patients after treatment with fluocinolone acetonide 0.1% in orabase. There was no significant difference in Candida counts between the groups (P > 0.05).
Our study indicates that using fluocinolone acetonide 0.1% in orabase to treat oral lichen planus for 3 months did not affect salivary lactoferrin protein secretion or Candida carriage. Trial registration The trial was registered at the Thai Clinical Trials Registry (TCTR identifier: TCTR20200723002).